메뉴 건너뛰기




Volumn 62, Issue 20, 2013, Pages 1842-1844

High-density lipoprotein and residual cardiovascular risk: De minimis non curat medicus or the COURAGE to be SMART?

Author keywords

HDL cholesterol; LDL cholesterol; secondary prevention; statins

Indexed keywords

ATORVASTATIN; DALCETRAPIB; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

EID: 84887160305     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.05.087     Document Type: Editorial
Times cited : (3)

References (23)
  • 1
    • 84887153834 scopus 로고    scopus 로고
    • Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication
    • for the SMART Study Group
    • A.P. van de Woestijne, Y. van der Graaf, A.-H. Liem, M.J.M. Cramer, J. Westerink, F.L.J. Visseren for the SMART Study Group Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication J Am Coll Cardiol 62 2013 1834 1841
    • (2013) J Am Coll Cardiol , vol.62 , pp. 1834-1841
    • Van De Woestijne, A.P.1    Van Der Graaf, Y.2    Liem, A.-H.3    Cramer, M.J.M.4    Westerink, J.5    Visseren, F.L.J.6
  • 2
    • 77955712458 scopus 로고    scopus 로고
    • HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial
    • P.M. Ridker, J. Genest, and S.M. Boekholdt HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
    • (2010) Lancet , vol.376 , pp. 333-339
    • Ridker, P.M.1    Genest, J.2    Boekholdt, S.M.3
  • 3
    • 34748887666 scopus 로고    scopus 로고
    • HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    • for the Treating to New Targets Investigators
    • P. Barter, A.M. Gotto, J.C. LaRosa for the Treating to New Targets Investigators HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
    • (2007) N Engl J Med , vol.357 , pp. 1301-1310
    • Barter, P.1    Gotto, A.M.2    Larosa, J.C.3
  • 4
    • 61549120401 scopus 로고    scopus 로고
    • Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: Results from PROVE IT-TIMI 22
    • the TIMI Study Group
    • K.K. Ray, C.P. Cannon, R. Cairns, D.A. Morrow, P.M. Ridker, E. Braunwald the TIMI Study Group Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arterioscler Thromb Vasc Biol 29 2009 424 430
    • (2009) Arterioscler Thromb Vasc Biol , vol.29 , pp. 424-430
    • Ray, K.K.1    Cannon, C.P.2    Cairns, R.3    Morrow, D.A.4    Ridker, P.M.5    Braunwald, E.6
  • 5
    • 84887150818 scopus 로고    scopus 로고
    • Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)
    • S. Acharjee, W.E. Boden, and P.M. Hartigan Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post-hoc analysis from the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) J Am Coll Cardiol 62 2013 1826 1833
    • (2013) J Am Coll Cardiol , vol.62 , pp. 1826-1833
    • Acharjee, S.1    Boden, W.E.2    Hartigan, P.M.3
  • 6
    • 70450081001 scopus 로고    scopus 로고
    • Major lipids, apolipoproteins, and risk of vascular disease
    • for the Emerging Risk Factors Collaboration
    • E. Di Angelantonio, N. Sarwar, P. Perry for the Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
    • (2009) JAMA , vol.302 , pp. 1993-2000
    • Di Angelantonio, E.1    Sarwar, N.2    Perry, P.3
  • 7
    • 44649140474 scopus 로고    scopus 로고
    • Association of loss-of-function mutations in the ABCA1 gene with HDL-C levels and risk of IHD
    • R. Frikke-Schmidt, B.G. Nordestgaard, and M.C. Stene Association of loss-of-function mutations in the ABCA1 gene with HDL-C levels and risk of IHD JAMA 299 2008 2524 2532
    • (2008) JAMA , vol.299 , pp. 2524-2532
    • Frikke-Schmidt, R.1    Nordestgaard, B.G.2    Stene, M.C.3
  • 9
    • 84864845456 scopus 로고    scopus 로고
    • Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study
    • B.F. Voight, G.M. Peloso, and M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
    • (2012) Lancet , vol.380 , pp. 572-580
    • Voight, B.F.1    Peloso, G.M.2    Orho-Melander, M.3
  • 10
    • 84874900480 scopus 로고    scopus 로고
    • HDL-C, clinical equipoise and vascular endothelial function. Expert reviews in cardiovascular diseases
    • S. Campbell, and J. Genest HDL-C, clinical equipoise and vascular endothelial function. Expert reviews in cardiovascular diseases Expert Rev Cardiovasc Ther 11 2013 343 353
    • (2013) Expert Rev Cardiovasc Ther , vol.11 , pp. 343-353
    • Campbell, S.1    Genest, J.2
  • 11
    • 77952708442 scopus 로고    scopus 로고
    • Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis
    • M. Jun, B. Zhu, and M. Tonelli Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
    • (2010) Lancet , vol.375 , pp. 1875-1884
    • Jun, M.1    Zhu, B.2    Tonelli, M.3
  • 12
    • 84870045994 scopus 로고    scopus 로고
    • Effects of dalcetrapib in patients with a recent acute coronary syndrome
    • for the dal-OUTCOMES Investigators
    • G.G. Schwartz, A.G. Olsson, M. Abt for the dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
    • (2012) N Engl J Med , vol.367 , pp. 2089-2099
    • Schwartz, G.G.1    Olsson, A.G.2    Abt, M.3
  • 13
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • for the AIM-HIGH Investigators
    • W.E. Boden, J.L. Probstfield, T. Anderson for the AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
    • (2011) N Engl J Med , vol.365 , pp. 2255-2267
    • Boden, W.E.1    Probstfield, J.L.2    Anderson, T.3
  • 14
    • 84877299845 scopus 로고    scopus 로고
    • HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
    • HPS2-THRIVE Collaborative Group
    • HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
    • (2013) Eur Heart J , vol.34 , pp. 1279-1291
  • 15
    • 78651379500 scopus 로고    scopus 로고
    • Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
    • A.V. Khera, M. Cuchel, and M. de la Llera-Moya Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
    • (2011) N Engl J Med , vol.364 , pp. 127-135
    • Khera, A.V.1    Cuchel, M.2    De La Llera-Moya, M.3
  • 16
    • 79959919890 scopus 로고    scopus 로고
    • Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease
    • C. Besler, K. Heinrich, and L. Rohrer Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J Clin Invest 121 2011 2693 2708
    • (2011) J Clin Invest , vol.121 , pp. 2693-2708
    • Besler, C.1    Heinrich, K.2    Rohrer, L.3
  • 17
    • 84859384527 scopus 로고    scopus 로고
    • Molecular mechanisms of vascular effects of high-density lipoprotein: Alterations in cardiovascular disease
    • C. Besler, T.F. Lüscher, and U. Landmesser Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease EMBO Mol Med 4 2012 251 268
    • (2012) EMBO Mol Med , vol.4 , pp. 251-268
    • Besler, C.1    Lüscher, T.F.2    Landmesser, U.3
  • 18
    • 79955677017 scopus 로고    scopus 로고
    • S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease
    • K.M. Argraves, A.A. Sethi, and P.J. Gazzolo S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease Lipids Health Dis 10 2011 70 82
    • (2011) Lipids Health Dis , vol.10 , pp. 70-82
    • Argraves, K.M.1    Sethi, A.A.2    Gazzolo, P.J.3
  • 19
  • 20
    • 33847368173 scopus 로고    scopus 로고
    • Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL
    • T. Vaisar, S. Pennathur, and P.S. Green Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 2007 746 756
    • (2007) J Clin Invest , vol.117 , pp. 746-756
    • Vaisar, T.1    Pennathur, S.2    Green, P.S.3
  • 22
    • 84872712625 scopus 로고    scopus 로고
    • 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
    • T.J. Anderson, J. Grégoire, and R.A. Hegele 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
    • (2013) Can J Cardiol , vol.29 , pp. 151-167
    • Anderson, T.J.1    Grégoire, J.2    Hegele, R.A.3
  • 23
    • 79955476272 scopus 로고    scopus 로고
    • Novel HDL-directed pharmacotherapeutic strategies
    • E.M. Degoma, and D.J. Rader Novel HDL-directed pharmacotherapeutic strategies Nat Rev Cardiol 8 2011 266 277
    • (2011) Nat Rev Cardiol , vol.8 , pp. 266-277
    • Degoma, E.M.1    Rader, D.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.